JP2013525819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525819A5 JP2013525819A5 JP2013509302A JP2013509302A JP2013525819A5 JP 2013525819 A5 JP2013525819 A5 JP 2013525819A5 JP 2013509302 A JP2013509302 A JP 2013509302A JP 2013509302 A JP2013509302 A JP 2013509302A JP 2013525819 A5 JP2013525819 A5 JP 2013525819A5
- Authority
- JP
- Japan
- Prior art keywords
- abundance
- concentration
- measured
- value
- potassium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 24
- 239000011591 potassium Substances 0.000 claims description 24
- 229910052700 potassium Inorganic materials 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 21
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- 229910052749 magnesium Inorganic materials 0.000 claims description 12
- 229940109239 creatinine Drugs 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 238000009533 lab test Methods 0.000 claims description 6
- 239000012491 analyte Substances 0.000 claims description 5
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims 9
- 239000013610 patient sample Substances 0.000 claims 2
- 238000008789 Direct Bilirubin Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33215410P | 2010-05-06 | 2010-05-06 | |
| US61/332,154 | 2010-05-06 | ||
| US37866810P | 2010-08-31 | 2010-08-31 | |
| US61/378,668 | 2010-08-31 | ||
| PCT/US2011/035583 WO2011140483A2 (en) | 2010-05-06 | 2011-05-06 | Validation of point-of-care test results by assessment of expected analyte relationships |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013525819A JP2013525819A (ja) | 2013-06-20 |
| JP2013525819A5 true JP2013525819A5 (https=) | 2014-06-19 |
Family
ID=44902517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013509302A Pending JP2013525819A (ja) | 2010-05-06 | 2011-05-06 | 予想される検体関係を評価することによるポイント・オブ・ケア検査結果の検証法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110276342A1 (https=) |
| EP (1) | EP2567339A4 (https=) |
| JP (1) | JP2013525819A (https=) |
| KR (1) | KR20130105301A (https=) |
| CA (1) | CA2798456A1 (https=) |
| WO (1) | WO2011140483A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8645306B2 (en) | 2010-07-02 | 2014-02-04 | Idexx Laboratories, Inc. | Automated calibration method and system for a diagnostic analyzer |
| US9151769B2 (en) * | 2010-07-02 | 2015-10-06 | Idexx Laboratories, Inc. | Automated calibration method and system for a diagnostic analyzer |
| US11676730B2 (en) | 2011-12-16 | 2023-06-13 | Etiometry Inc. | System and methods for transitioning patient care from signal based monitoring to risk based monitoring |
| US20130231949A1 (en) | 2011-12-16 | 2013-09-05 | Dimitar V. Baronov | Systems and methods for transitioning patient care from signal-based monitoring to risk-based monitoring |
| EP2685264B1 (en) * | 2012-07-13 | 2020-12-02 | Idexx Laboratories, Inc. | Automated calibration method and system for a diagnostic analyzer |
| US20140222463A1 (en) * | 2013-01-31 | 2014-08-07 | Abbott Cardiovascular Systems Inc. | Enhanced monitoring |
| US11036779B2 (en) * | 2018-04-23 | 2021-06-15 | Verso Biosciences, Inc. | Data analytics systems and methods |
| WO2020080491A1 (ja) * | 2018-10-17 | 2020-04-23 | 株式会社 資生堂 | 血液中のクレアチニン量に基づく腎機能検査結果の妥当性を検定する方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK409188D0 (da) * | 1988-07-21 | 1988-07-21 | Radiometer As | Fremgangsmaade til maaling af en karakteristik i et fluidum |
| JP2828609B2 (ja) * | 1994-09-22 | 1998-11-25 | 株式会社エイアンドティー | 臨床検査分析装置 |
| US6015667A (en) * | 1996-06-03 | 2000-01-18 | The Perkin-Emer Corporation | Multicomponent analysis method including the determination of a statistical confidence interval |
| JP2001331581A (ja) * | 2000-05-22 | 2001-11-30 | Yusuke Tsukamoto | 自動診断システム、自動診断方法、治療法自動決定システム、治療法自動決定方法及び記録媒体 |
| IL152740A0 (en) * | 2000-05-31 | 2003-06-24 | Fasttrack Systems Inc | Clinical trials management system and method |
| WO2003019184A1 (en) * | 2001-08-24 | 2003-03-06 | Bio-Rad Laboratories, Inc. | Biometric quality control process |
| US20060160074A1 (en) * | 2001-12-27 | 2006-07-20 | Third Wave Technologies, Inc. | Pharmacogenetic DME detection assay methods and kits |
| US7177767B2 (en) * | 2002-10-18 | 2007-02-13 | Abaxis, Inc. | Systems and methods for the detection of short and long samples |
| ES2334671T3 (es) * | 2004-08-13 | 2010-03-15 | Egomedical Technologies Ag | Sistema de ensayo de analitos para determinar la concentracion de un analito en un fluido fisiologico o acuoso. |
| US8112232B2 (en) * | 2007-02-02 | 2012-02-07 | Beckman Coulter, Inc. | System and method for autoverifying laboratory test results |
| JP5164646B2 (ja) * | 2008-04-08 | 2013-03-21 | 国立大学法人高知大学 | 臨床検査データ解析支援装置、臨床検査データ解析支援方法及びそのプログラム |
| JP4872103B2 (ja) * | 2009-02-05 | 2012-02-08 | 国立大学法人 大分大学 | 臨床検査値の管理装置、管理方法及び管理プログラム |
| US20110046919A1 (en) * | 2009-03-02 | 2011-02-24 | Juliesta Elaine Sylvester | Method for accurate measurement of enzyme activities |
-
2011
- 2011-05-06 EP EP20110778441 patent/EP2567339A4/en not_active Withdrawn
- 2011-05-06 US US13/102,394 patent/US20110276342A1/en not_active Abandoned
- 2011-05-06 CA CA2798456A patent/CA2798456A1/en not_active Abandoned
- 2011-05-06 JP JP2013509302A patent/JP2013525819A/ja active Pending
- 2011-05-06 WO PCT/US2011/035583 patent/WO2011140483A2/en not_active Ceased
- 2011-05-06 KR KR1020127031906A patent/KR20130105301A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ogata et al. | Ultra-sensitive serial profiling of SARS-CoV-2 antigens and antibodies in plasma to understand disease progression in COVID-19 patients with severe disease | |
| Dayon et al. | Proteomics of human biological fluids for biomarker discoveries: technical advances and recent applications | |
| Yekula et al. | From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers | |
| JP2013525819A5 (https=) | ||
| JP2025172836A (ja) | 自閉症スペクトラム障害のリスクを決定するための方法およびシステム | |
| JP7665071B2 (ja) | 試料の品質評価方法 | |
| EP3318995A1 (en) | Methods and apparatus for identifying disease status using biomarkers | |
| EP3440465A2 (en) | Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps | |
| WO2013119871A1 (en) | A multi-biomarker-based outcome risk stratification model for pediatric septic shock | |
| Spick et al. | Systematic review with meta-analysis of diagnostic test accuracy for COVID-19 by mass spectrometry | |
| CA2798456A1 (en) | Validation of point-of-care test results by assessment of expected analyte relationships | |
| Obstfeld et al. | Data mining approaches to reference interval studies | |
| CN115144599A (zh) | 蛋白组合在制备对儿童甲状腺癌进行预后分层的试剂盒中的用途及其试剂盒、系统 | |
| US20210010083A1 (en) | Temporal pediatric sepsis biomarker risk model | |
| Burroughs et al. | Non-invasive tests for liver fibrosis: encouraging or discouraging results? | |
| Fang et al. | Prognostic biomarkers based on proteomic technology in COPD: a recent review | |
| Kiechle et al. | Establishing benchmarks and metrics for disruptive technologies, inappropriate and obsolete tests in the clinical laboratory | |
| Mollee et al. | Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis | |
| Arneth et al. | The use of kappa free light chains to diagnose multiple sclerosis | |
| CN113936739A (zh) | 新型冠状病毒样本碱基突变自动评估方法 | |
| US10261068B2 (en) | Persevere-II: redefining the pediatric sepsis biomarker risk model with septic shock phenotype | |
| Walter et al. | Accuracy of p53 codon 72 polymorphism status determined by multiple laboratory methods: a latent class model analysis | |
| US12152269B2 (en) | Examination system, examination device, and examination method for testing sample quality prior to biomarker detection | |
| Shastry et al. | Sub-phenotypes of pneumonia defined by pulmonary histopathological features | |
| Chen et al. | Development of fibrotic gene signature and construction of a prognostic model in melanoma |